Evidence map›Paper›PMID 32630441›Full record

ArticleJournal of clinical medicine2020

Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis-Part B.

Canay Caliskan, Benjamin Seeliger, Benedikt Jäger, Jan Fuge, Tobias Welte, Oliver Terwolbeck, Julia Freise, Coline H M van Moorsel, Yingze Zhang, Antje Prasse

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Towards Treatable Traits for Pulmonary Fibrosis.Journal of personalized medicine · 2022
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Canay CaliskanDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.ORCID 0000-0002-9177-1032
Benjamin SeeligerDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.ORCID 0000-0001-7373-752X
Benedikt JägerFraunhofer Institute for Toxicology and Experimental Medicine, 30625 Hannover, Germany.
Jan FugeDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.
Tobias WelteDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.
Oliver TerwolbeckFraunhofer Institute for Toxicology and Experimental Medicine, 30625 Hannover, Germany.
Julia FreiseDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.
Coline H M van MoorselDept of Pulmonology, Interstitial Lung Diseases Center of Excellence, St Antonius Hospital, 3435 CM Nieuwegein, The Netherlands.
Yingze ZhangDepartment of Medicine and Human Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-6947-2901
Antje PrasseDepartment of Respiratory Medicine, Hannover Medical School and Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Lung Research Center (DZL), 30265 Hannover, Germany.
Medizinische Hochschule Hannover · DEFraunhofer Institute for Toxicology and Experimental Medicine · DESt. Antonius Ziekenhuis · NLUniversity of Pittsburgh · US

Funding

Deutsche Forschungsgemeinschaft ME 3696/3-1
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with high mortality. CC-chemokine ligand 18 (CCL18) is predictive of survival in IPF. We described correlation of CCL18 serum levels with the genotype of

Indexed as

antifibroticsCCL18idiopathic pulmonary fibrosisinterstitial lung disease

Identifiers

PMID32630441
PMCPMC7356861
OpenAlexW3036020225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.